We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+8.23%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.74B
AUM Growth
-$74.6M
Cap. Flow
-$193M
Cap. Flow %
-5.15%
Top 10 Hldgs %
49.32%
Holding
151
New
26
Increased
20
Reduced
26
Closed
34

Top Buys

Rank Stock Value
1
CRNX
Crinetics Pharmaceuticals
CRNX
+$76.8M
2
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.1M
3
VRAY
ViewRay, Inc.
VRAY
+$35.6M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$21.3M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$20.4M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$65.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$64.5M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$57.5M
4
HUM icon
Humana
HUM
+$36.8M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.11%
2 Miscellaneous 5.71%
3 Consumer Staples 0.92%
4 Financials 0.17%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TDOC icon
126
Teladoc Health
TDOC
$1.2B
– –
-195,000
Closed -$11.3M
TGTX icon
127
TG Therapeutics
TGTX
$8.12B
– –
-100,000
Closed -$258K
VRNA
128
DELISTED
Verona Pharma
VRNA
– –
-22,327
Closed -$307K
VRTX icon
129
Vertex Pharmaceuticals
VRTX
$130B
– –
-75,898
Closed -$12.9M
YARW
130
Yarrow Bioscience
YARW
$68.1M
– –
-345
Closed -$10.1M
GRDX
131
GridAI Technologies Corp
GRDX
$21.5M
– –
-2
Closed -$730K
GRCE
132
Grace Therapeutics
GRCE
$46.9M
– –
-4,306
Closed -$117K
MRTX
133
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-713,191
Closed -$35.2M
ONCT
134
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-10,725
Closed -$23M
FRTX
135
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-3,628
Closed -$1.31M
AGRX
136
DELISTED
Agile Therapeutics
AGRX
– –
-1,765
Closed -$1.74M
ELOX
137
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
– –
-74
Closed -$50K
FLXN
138
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-307,989
Closed -$7.96M
SBBP
139
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-275,000
Closed -$1.65M
ALXN
140
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-463,450
Closed -$57.5M
AVEO
141
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-189,119
Closed -$4.27M
BOLD
142
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-660,406
Closed -$25.2M
ARRY
143
DELISTED
Array Biopharma Inc
ARRY
– –
-40,133
Closed -$673K
LOXO
144
DELISTED
Loxo Oncology, Inc
LOXO
– –
-3,765
Closed -$653K
ATHN
145
DELISTED
Athenahealth, Inc.
ATHN
– –
-150,000
Closed -$23.9M
2 3 4 5
6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Perceptive Advisors held 151 positions worth $3.74B, down 2% from $3.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Perceptive Advisors withdrew a net $193M in Q3 2018, closing 34 positions and reducing 26 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $57.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Crinetics Pharmaceuticals worth $74.1M.

  • Perceptive Advisors's largest Q3 2018 buy was Crinetics Pharmaceuticals: 2,587,953 shares worth $74.1M.
  • Perceptive Advisors added most to Athenex, Inc. Common Stock in Q3 2018, an estimated $47.1M increase.
  • Perceptive Advisors's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $65.3M.
  • Perceptive Advisors fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $57.5M.
  • Perceptive Advisors's ten largest holdings make up 49% of its $3.74B portfolio in Q3 2018.
  • Perceptive Advisors opened 26 new positions and closed 34 in Q3 2018.
  • Perceptive Advisors's portfolio value fell 2% quarter-over-quarter to $3.74B.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.